Eduard Diviu, BD and Eng.
CEO, Co-founder and Chairman of the Board at Sagetis Biotech.
With a business and engineering background, a marked entrepreneurial profile and a hands-on, science driven approach with a global view, Eduard has played a key role in the successful rise of capital since the company foundation. Eduard is also involved in the negotiations with Pharma companies and the establishment of IP strategies. He is skilful in management, human resources and setting up and executing strategic plans.
Salvador Borrós, PhD.
CSO, Co-founder and member of the Board at Sagetis Biotech. Full Professor at IQS. PhD in Chemical Engineering. Scientific Leader of Material Engineering Group (GEMAT). Member of the IQS's Bioengineering Department.
Vast and proven experience, amongst others, in Materials Science (Chemistry and Chemical Engineering), Materials Science Fundamentals (Industrial Engineering), Materials Technology (Industrial Engineering), Materials Selection, Polymeric and Ceramics Materials, Biomaterials and Medical Devices (where he also holds a Master in Bioengineering).
Noteworthy, he has robust knowledge and experience in Biomaterials (Stimuli sensitive polymeric nanoparticles for drug delivery; Design of biomimetic surfaces with both chemical and mechanical signalling) and Smart surfaces (Design and rapid manufacturing fabrication of scaffolds for bone and cartilage regeneration). Salvador is a cornerstone in the development and of Sagetis technology platform and the generation of intellectual property around it. He has over 110 publications and 17 patents and is in charge of the research activities carried out at Sagetis.
Xavier Rivero, BSc
COO and partner at Sagetis Biotech.
Seasoned professional with more than 30 years in the pharmaceutical industry, in particular in R&D and business development.
Driven by passion for differentiated, innovative products that cover unmet needs. Xavier is in charge of the Development activities carried out by the company in coordination with CROs and CMOs. He has designed the Development activities that have been key for obtaining Venture Capital for the company. Xavier has been also a key figure to assess the potential risks and solutions to transform Sagetis technologies into feasible products.
Anna Cascante, PhD
Head of Molecular and Cellular Biology/Head of Laboratory.
PhD in Biochemistry and Molecular Biology with extensive experience in gene therapy strategies and oncology through her experience in several postdoc positions. With a pharmaceutics background and a pragmatic, down to earth approach, Anna is also the head of laboratory and a key person in the transition of the R&D candidates into formulations that can be eventually turned into medicines for human use. Anna has also several peer reviewed publications and patents.
Josep Lamarca, MD
Business Development and partner at Sagetis Biotech
MD in Neuropathology. Seasoned executive with a broad background in business development including in and out-licensing transactions. Josep has a proven track record of in and out licensing deals in both US, Japan and Europe and has a vast experience of interaction with pharma, biotech and drug delivery technology companies worldwide. Josep has also established long term relationship with pharma companies in Japan and built up partnerships with leading multidisciplinary teams in the partnering process.
Besides, he has wide experience in different types of deals, from early-stage projects to commercial products, also supervising the Quality of secondary agreements. Josep has a vast experience in the preparation of in- and out-licensing strategies, and setting up internal protocols for project evaluation. He has participated as member of corporate staff, in the corporate strategic plan of a multinational pharmaceutical company. Prior to his experience in the industry, he conducted medical practice, medical education and biomedical research in neurobiology leading to original publications in the US and EU.